share_log

Salix to Present Late-Breaking Data From Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data From Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix將在2024年消化系統疾病週上公佈阿米塞莫德治療活動性潰瘍性結腸炎的2期試驗的最新數據
Bausch Health ·  05/17 12:00

LAVAL, Quebec, May 17, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C.

魁北克省拉瓦爾,2024年5月17日——Bausch Health Companies Inc.(紐約證券交易所/多倫多證券交易所代碼:BHC)及其胃腸病學(GI)業務Salix Pharmicals今天宣佈,他們將公佈其評估阿米塞莫德作爲活動性潰瘍性結腸炎(UC)治療藥物的2期試驗的數據。這些數據將於2024年5月19日星期日在華盛頓特區舉行的IMIBD Late Breakers and Innovations in IBD會議期間在2024年消化疾病周(DDW)上公佈。

"We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1- phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC," said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health. "The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC."

Bausch Health首席醫學官兼研發總裁Tage Ramakrishna醫學博士說:“我們很高興提供有關Amiselimod的最新數據,Amiselimod是我們的研究性口服鞘氨醇1-磷酸鞘醇(S1P)受體調節劑,可作爲誘導UC緩解的潛在治療方法。”“該摘要凸顯了我們對爲UC患者開發新的創新療法的堅定承諾。”

The research to be featured at DDW 2024 and available via the meeting's online platform is as follows:

該研究將在DDW 2024上展出,並可通過會議的在線平台獲取,如下所示:

  • Hanauer, Stephen B. et al. "Amiselimod for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled trial" Abstract #4094796
  • Hanauer、Stephen B. 等“用於治療活動性潰瘍性結腸炎的阿米塞莫德:一項隨機、雙盲、安慰劑對照試驗” 摘要 #4094796

The Phase 2 clinical trial was a 12-week, double-blind, placebo-controlled, randomized, dose ranging study to evaluate the efficacy and safety of Amiselimod in 320 patients with mildly-to- moderately active UC. Bausch Health announced positive topline results from this study in December 2023.

2期臨床試驗是一項爲期12周的雙盲、安慰劑對照、隨機、劑量範圍的研究,旨在評估阿米塞莫德對320名輕度至中度活性UC患者的療效和安全性。Bausch Health 宣佈 積極的頂線結果 摘自 2023 年 12 月的這項研究。

About Amiselimod
Amiselimod is a sphingosine-1-phosphate (S1P) receptor functional antagonist and, by inhibiting the receptor function of the lymphocyte sphingosine-1-phosphate (S1P) receptor, retains lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions.1 Due to this mechanism of action, Amiselimod may potentially be useful for various autoimmune diseases.2 Affinity to S1P1 and S1P5 receptor subtypes, suggests that Amiselimod could potentially have a more pronounced effect on ulcerative colitis related inflammation than compounds with restricted activity on S1P1 receptor subtype exclusively or combined activity on S1P1 and S1P5.3

關於阿米塞莫德
Amiselimod 是一種鞘氨醇-1-磷酸 (S1P) 受體功能拮抗劑,通過抑制淋巴細胞鞘氨醇-1-磷酸 (S1P) 受體的受體功能,可保留淋巴結中封存的淋巴細胞,防止它們促成自身免疫反應。1 由於這種作用機制,阿米塞莫德可能可用於各種自身免疫反應。1 由於這種作用機制,阿米塞莫德可能可用於各種自身免疫反應。免疫性疾病。2 對S1P1和S1P5受體亞型的親和力表明,阿米塞莫德對潰瘍性結腸炎相關炎症的影響可能比化合物更爲明顯僅對 S1P1 受體亞型的活性有限,或者對 S1P1 和 S1P5 具有組合活性。3

About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and provide health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and Linkedin

關於 Salix
Salix Pharmaceuticals是世界上最大的專業製藥公司之一,致力於預防和治療胃腸道疾病。30多年來,Salix一直在許可、開發和銷售創新產品,以改善患者的生活,併爲醫療保健提供者提供針對許多慢性和虛弱性疾病的改變生活的解決方案。Salix目前通過擴大銷售隊伍,向美國醫療保健提供商銷售其產品線,該銷售隊伍側重於胃腸病學、肝病學、疼痛專家和初級保健。Salix 總部位於新澤西州布里奇沃特。有關 Salix 的更多信息,請訪問 www.salix.com 然後通過以下方式聯繫我們 推特領英

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.comand connect with us on Twitter and LinkedIn.

關於 Bausch 健康
Bausch Health Companies Inc.(紐約證券交易所代碼:BHC)(多倫多證券交易所股票代碼:BHC)是一家全球多元化製藥公司,通過我們不懈地努力提供更好的健康結果,豐富生活。我們通過在Bausch + Lomb的控股權開發、製造和銷售一系列產品,主要涉及胃腸病學、肝病學、神經病學、皮膚科、醫學美容設備、國際藥品和眼部健康。我們的目標是成爲一家全球綜合醫療保健公司,受到患者、HCP、員工和投資者的信任和重視。欲了解更多信息,請訪問 www.bauschhealth.com並通過以下方式聯繫我們 推特領英

About DDW Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 18-21, 2024. The meeting showcases more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

關於 DDW 消化道疾病周(DDW)是胃腸病學、肝病學、內窺鏡檢查和胃腸道外科領域最大的醫生、研究人員和學者國際聚會。DDW由美國肝臟疾病研究協會(AASLD)、美國胃腸病學會(AGA)、美國胃腸道內窺鏡學會(ASGE)和消化道外科學會(SSAT)共同贊助,是一次面對面的在線會議,將於2024年5月18日至21日舉行。會議展示了有關胃腸道研究、醫學和技術最新進展的4,400多份摘要和數百場講座。更多信息可以在以下網址找到 www.ddw.org

References

參考文獻

  1. Kunio Sugahara, Yasuhiro Maeda. Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. British Journal of Pharmacology. January 2017.
  2. Peyrin-Biroulet, Ronald Christopher Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmunity Reviews. February 2017.
  3. BiseraStepanovska, AndreaHuwiler. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacological Research. February 2019.
  1. 菅原邦雄,前田康博。阿米塞莫德是一種新型鞘氨醇1磷酸受體1調節劑,對自身免疫性疾病具有強大的治療功效,心動過緩風險低。英國藥理學雜誌。2017 年 1 月。
  2. Peyrin-Biroulet,Ronald Christopher 炎症性腸病中鞘氨醇-1-磷酸的調節。自身免疫評論。2017 年 2 月。
  3. 比塞拉斯·斯特帕諾夫斯卡,安德里亞·休維勒。靶向S1P受體信號通路是治療自身免疫和炎症性疾病的一種有前途的方法。藥理研究。2019 年 2 月。

2024 Salix Pharmaceuticals or its affiliates.
UNB.0018.USA.24

2024 薩利克斯製藥或其附屬公司。
UNB.0018.USA.24

Investor Contact: Media Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll-free)
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785
投資者聯繫人: 媒體聯繫人:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642(免費電話)
凱文威金斯
corporate.communications@bauschhealth.com
(908) 541-3785

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論